ReviewExpert review of anti-infective therapy2018
Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence.
Review in Expert review of anti-infective therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 91 citations in OpenAlex.
- Effectiveness of Long-lasting Insecticide-Impregnated Bed Nets in Controlling Phlebotomus argentipes in Sri Lanka: A Cluster Randomized Controlled Trial.The Journal of infectious diseases · 2025Trial
- Leishmania Extracellular Vesicles as a Preventive Vaccine Platform Against Leishmaniasis.Journal of extracellular vesicles · 2026Article
- Presence of localized elevated metabolic enzymes and kdr mutations in the voltage-gated sodium channel gene indicate early evidence of resistance of Phlebotomus argentipes to alpha-cypermethrin in Bihar, India.Parasites & vectors · 2026Article
- Molecular docking: a computational approach for the discovery of novel targets against visceral leishmaniasis.Journal of molecular modeling · 2026Review
- Targeting environmental determinants and settlements in public health planning for the containment of visceral leishmaniasis: a One Health perspective.Frontiers in public health · 2026Article
- Leishmaniasis.Nature reviews. Disease primers · 2025Review
- Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India.PLoS neglected tropical diseases · 2025Article
- Contribution of imaging in the diagnosis of three neglected diseases in the Southern Cone: Leishmaniasis, Dengue, and Chikungunya.Pediatric radiology · 2025Review
- An exploration of current and future vector-borne disease threats and opportunities for change.Frontiers in public health · 2025Article
- Visceral Leishmaniasis Service Delivery in Somalia: A Comprehensive Literature Review.Research and reports in tropical medicine · 2025Review
- Salivary antigens rPagSP02 and rPagSP06 are a reliable composite biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka.Scientific reports · 2024Article
- Active Community-Based Case Finding of Endemic Leishmaniasis in West Bengal, India.Journal of epidemiology and global health · 2024Article
- Article
- rPagSP02+rPagSP06 recombinant salivary antigen is a reliable biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka.Research square · 2024Article
- Challenges for maintaining post elimination phase of visceral leishmaniasis control programme in India: A field-based study.PLoS neglected tropical diseases · 2024Article
- Articulate Chemotherapeutic Strategies for the Development of Effective Drugs against a Fatal Disease, Visceral Leishmaniasis.Current drug discovery technologies · 2024Review
- Determinants of Visceral Leishmaniasis in Addis Zemen Health Center, Northwest Ethiopia.Journal of tropical medicine · 2024Article
- Article
- Article
- Molecular surveillance of insecticide resistance in Phlebotomus argentipes targeted by indoor residual spraying for visceral leishmaniasis elimination in India.PLoS neglected tropical diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionVisceral leishmaniasis (VL) is a fatal parasitic disease caused by a parasite belonging to the Leishmania donovani complex and transmitted by infected female Phlebotomous argentipes sand flies. The VL elimination strategy in the Indian subcontinent (ISC), which has a current goal of reducing the incidence of VL to below 1/10,000 of population by the year 2020, consists of rapid detection and treatment of VL to reduce the number of human reservoirs as well as vector control using indoor residual spraying (IRS). However, as the incidence of VL declines toward the elimination goal, greater targeting of control methods will be required to ensure appropriate early action to prevent the resurgence of VL. Area covered: We discuss the current progress and challenges in the VL elimination program and strategies to be employed to ensure sustained elimination of VL. Expert commentary: The VL elimination initiative has saved many human lives; however, for VL elimination to become a reality in a sustained way, an intense effort is needed, as substantial numbers of endemic subdistricts (primary health centers (PHCs) blocks level) are yet to reach the elimination target. In addition to effective epidemiological surveillance, appropriate diagnostic and treatment services for VL at PHCs will be needed to ensure long-term sustainability and prevent reemergence of VL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.